Abstracting and indexing is the process by which a bibliographic database systematically catalogs a journal’s articles, capturing standardized metadata such as titles, authors, affiliations, abstracts, keywords and references, and making that metadata searchable across a global platform. The practical consequence for researchers is discoverability. An article that appears only on an individual journal website exists in a kind of bibliographic isolation, reachable mainly by readers who already know the journal. Once a journal is indexed in the Science Citation Index Expanded, its content becomes discoverable through Web of Science search tools, its citation links become traceable through the database’s cited-reference searching, and its cumulative performance becomes visible to the librarians, funders and evaluation committees who rely on these databases when they assess journals and institutions. In an era when most literature discovery begins with a database query rather than a browse of a journal’s table of contents, indexing status is a structural determinant of a paper’s audience.

The Science Citation Index Expanded is the multidisciplinary extension of the original Science Citation Index, the citation database created by Eugene Garfield in the 1960s and now maintained as part of the Web of Science Core Collection. The index covers thousands of journals across the natural sciences, applied sciences and medicine, and its selection process is deliberately selective. Editors evaluating a journal for inclusion consider a range of quality signals: the rigor and consistency of peer review, the international diversity of the editorial board and authorship, the regularity of publication, the ethical publishing standards in place, and the citation behavior of the journal’s published content. Journals are re-evaluated continuously, and inclusion is not permanent, which means that a journal’s presence in the index is itself an ongoing signal that its editorial standards continue to meet the database’s criteria.

The impact factor reported alongside the indexing record is the metric most closely watched by authors deciding where to submit their work. Calculated annually by Clarivate from the citation data in the Web of Science, the two-year impact factor for a given year is the ratio of citations received in that year to the number of substantive items, typically articles and reviews, published in the journal during the two preceding years. A 2022 impact factor of 5.5 therefore reflects citations accumulated in 2022 by papers published in 2020 and 2021, divided by the count of those papers. For a journal that entered the index in 2021, this figure arrives early in its indexed life, since new journals typically need a settling period before their citation patterns stabilize. The value of 5.5 indicates that, on average, each citable item published in the journal during the measurement window drew more than five citations in the following year, a level of citation intensity that corresponds to a strong, internationally visible research venue in the pharmaceutical field.

Quartile placement translates that raw number into context. Journals in a Web of Science category are ranked by impact factor and divided into four groups, with the first quartile, Q1, containing the top 25 percent. The Journal of Pharmaceutical Investigation’s position at 48 out of 278 journals in Pharmacology and Pharmacy places it firmly within that top band, ahead of roughly four-fifths of the journals in its category. The rank matters because impact factors are meaningful only in comparison. A value of 5.5 might be modest in a field with extremely high citation rates and exceptional in a field where citation density is low; the quartile ranking situates the journal relative to the actual distribution of its peers in pharmacology and pharmacy. Authors evaluating potential outlets, and readers skimming reference lists for authoritative sources, use these rankings as a fast heuristic for gauging where a journal stands within its discipline.

The downstream effects of this status are practical for the research community. Authors gain a publication venue whose indexed metrics can be cited in grant applications, promotion dossiers and funder reports, where journal quality is often assessed through Web of Science-based indicators. Institutions benefit because their researchers’ publications contribute to institutional citation profiles and to the global university rankings that draw heavily on Web of Science data. Readers benefit from the cited-reference network that the index builds, allowing them to trace the lineage of a finding backward through earlier work and forward through later citations. Librarians use the indexing record and the impact factor when making subscription decisions, which in turn supports the journal’s financial sustainability. In this way, a single indexing milestone ripples outward through nearly every stakeholder in the scientific communication system.

The pharmaceutical sciences present a particularly demanding environment for journal metrics. The field spans drug discovery, formulation science, pharmacokinetics, drug delivery systems, clinical pharmacology and regulatory science, and its publication landscape is crowded with long-established titles backed by major societies and commercial publishers. Citation behavior in the field is shaped by translational urgency: work on delivery platforms, biologics and therapeutic development often draws attention from both basic researchers and clinical communities, which can drive citation counts upward for journals positioned at those intersections. A journal focused on pharmaceutical investigation sits naturally in that translational zone, and the first-quartile ranking suggests that its published research is being picked up across both the pharmaceutical technology and the pharmacology communities that make up its readership.

At the same time, the announcement is a fitting occasion to recall the limits of the metrics involved. The research community has increasingly emphasized responsible use of quantitative indicators. The San Francisco Declaration on Research Assessment, signed by thousands of journals, funders and institutions, urges that impact factors not be used as a surrogate for the quality of individual papers or the merit of individual researchers, since citation counts are influenced by article type, review articles inflate averages, and two-year windows capture only a slice of a paper’s scholarly lifetime. Altitude within a quartile shifts year to year as citation patterns fluctuate, and a journal’s impact factor is a property of the journal, not a guarantee about any single article it publishes. The appropriate reading of the 2022 record is therefore as a signal of the journal’s overall standing and editorial health, not as a per-article quality certificate.

For the broader community of pharmaceutical researchers, the development adds one more indexed, first-quartile outlet to a field where the demand for visible, credible publication venues remains intense. Inclusion in the Science Citation Index Expanded from 2021 onward means that the journal’s recent volumes are being woven into the global citation fabric that underlies literature search, systematic review, bibliometric analysis and research evaluation. Its 2022 impact factor of 5.5 and its Q1 position at 48 of 278 journals in Pharmacology and Pharmacy provide a quantified snapshot of that integration. Whether the journal sustains and improves those numbers will depend on the same fundamentals that determine any journal’s trajectory: the quality and relevance of the research it attracts, the rigor of its peer review, and its continued adherence to the editorial standards that earned it entry into one of scholarly publishing’s most closely watched databases.

Subject of Research: Indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its 2022 impact factor of 5.5 in pharmacology and pharmacy.

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: abstracting and indexing, Science Citation Index Expanded, impact factor, Journal of Pharmaceutical Investigation, pharmacology, pharmacy, Web of Science, quartile ranking, scholarly publishing, pharmaceutical sciences, journal metrics, research visibility

Abstracting and indexing is the process by which a journal’s published articles are systematically catalogued in major bibliographic databases, allowing them to be discovered, cited, and tracked by the global research community. Inclusion in the Science Citation Index Expanded, one of the core citation databases maintained within the Web of Science platform, signals that a journal has passed a rigorous editorial evaluation covering publishing standards, editorial board composition, peer-review integrity, international diversity of authorship, and the consistency of its scholarly output. For pharmaceutical researchers, this means that articles appearing in the journal are now fully searchable alongside the most influential literature in pharmacology and pharmacy, and that citations to those articles are counted in official journal metrics.

The Impact Factor, the most widely recognized of these metrics, is calculated by dividing the number of citations received in a given year by articles published in the two preceding years. A value of 5.5 for 2022 indicates that, on average, papers published in the journal during 2020 and 2021 were cited 5.5 times in 2022. This figure places the journal comfortably within the upper tier of its category, since quartile rankings divide the journals in a subject class into four equal groups by citation performance. A Q1 designation, corresponding to the top 25 percent of the 278 journals ranked in Pharmacology and Pharmacy, is a benchmark many institutions use when assessing publication quality for hiring, promotion, and funding decisions.

The rank of 48 out of 278 is particularly notable in a category as large and competitive as Pharmacology and Pharmacy, which spans everything from basic molecular pharmacology to clinical therapeutics and pharmaceutical manufacturing. Journals in this category compete for citations from a vast body of global research, and moving into the first quartile typically requires sustained growth in both the quality and the visibility of published work. For a journal focused specifically on pharmaceutical investigation, the achievement reflects the growing citation footprint of research on drug delivery systems, nanomedicine, pharmacokinetics, and the formulation technologies that translate laboratory discoveries into clinical products.

Indexing in SciSearch since 2021 means the journal’s metrics are still relatively young within the Web of Science ecosystem, which makes the 2022 Impact Factor an early but meaningful indicator of its trajectory. New journals often take several years to accumulate the citation history needed for stable rankings, and early Impact Factors can fluctuate as the indexed back-file grows. A first-quartile placement within roughly two years of indexing suggests that the journal’s existing body of work was already attracting substantial citations, and that its inclusion in the database made that influence visible to the evaluators, librarians, and researchers who rely on these metrics to navigate the literature.

The practical consequences of indexing and quartile performance extend well beyond prestige. Researchers choosing where to submit manuscripts frequently consult journal rankings to maximize the reach and career value of their work, and many funding agencies and universities maintain lists of approved outlets based on Web of Science categories and quartiles. Librarians use the same data to make subscription decisions. For authors in pharmaceutical sciences, a Q1 journal with a 5.5 Impact Factor offers a combination of disciplinary focus and broad discoverability that can accelerate the uptake of new methods, from controlled-release formulations to novel excipients and biopharmaceutical characterization techniques.

Bibliometric experts caution, however, that the Impact Factor is a blunt instrument. It measures average citations to a two-year window of articles and can be influenced by a small number of highly cited reviews, by the overall volume of publication, and by citation practices that vary across subfields. Pharmacology and pharmacy journals, which sit at the interface of basic science and applied medicine, often benefit from citation patterns that differ from those of purely clinical or purely basic titles. For this reason, evaluators are increasingly encouraged to read quartile rankings alongside other indicators, such as the journal’s scope, its peer-review standards, and the actual readership of individual papers rather than journal-level averages alone.

Even with those caveats, the formal recognition matters for the research community the journal serves. Pharmaceutical investigation is a field in which translational timelines are long and the path from molecular discovery to approved therapy depends on shared methodological standards. When a specialized journal achieves first-quartile status, it strengthens the visibility of the applied and formulation-oriented research that often falls between the traditional categories of pharmacology and chemical engineering. This can help ensure that advances in drug delivery technology, bioequivalence assessment, and pharmaceutical quality control receive the same citation attention as breakthroughs in target discovery or clinical trial results.

The journal’s listing with Springer, which publishes the title as part of its pharmaceutical sciences portfolio, provides the authoritative record of its indexing status and metric performance. The publisher’s announcement confirms both the 2021 start of Science Citation Index Expanded coverage and the 2022 Impact Factor of 5.5, along with the category rank of 48 out of 278 in Pharmacology and Pharmacy. These figures will be updated annually as new citation data become available, and the journal’s position will be watched by authors, editors, and bibliometric analysts alike as an indicator of how specialized pharmaceutical research titles fare in an increasingly metrics-driven publishing environment.

For the broader scientific publishing landscape, the case illustrates how abstracting and indexing functions as the gateway through which journals enter the formal economy of scholarly recognition. Without inclusion in the major citation databases, even high-quality research risks invisibility in the evaluations that shape careers and funding. With inclusion, and with a strong early Impact Factor, a journal can rapidly become a destination for the work that defines its field. The Journal of Pharmaceutical Investigation’s Q1 standing demonstrates that a focused pharmaceutical title can achieve that recognition quickly, provided its published research resonates with the citation behavior of the international pharmacology and pharmacy community.

Subject of Research: Indexing of the Journal of Pharmaceutical Investigation in Science Citation Index Expanded and its 2022 Impact Factor of 5.5 with a Q1 rank of 48/278 in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, quartile ranking, pharmacology and pharmacy, Web of Science, bibliometrics, pharmaceutical sciences, Springer, citation metrics

To understand why this matters, it helps to unpack what indexing in the Science Citation Index Expanded actually means. The Science Citation Index Expanded is one of the core citation databases maintained within the Web of Science, the citation ecosystem originally built on Eugene Garfield’s pioneering work at the Institute for Scientific Information. Inclusion is not automatic. Journals seeking coverage undergo a rigorous evaluation process in which publishers submit documentation of editorial standards, peer review practices, editorial board composition, publication ethics policies, and the international diversity of authorship. Clarivate’s editorial development team assesses whether the journal meets the quality thresholds for foundational coverage and whether its citation performance justifies admission. Being accepted into SciSearch in 2021 signaled that the Journal of Pharmaceutical Investigation had cleared one of the most demanding quality gates in scholarly publishing, a gate that thousands of journals worldwide never pass.

Indexing, in turn, is the precondition for the metric that has become the lingua franca of journal evaluation: the Impact Factor. Calculated annually by Clarivate from the Journal Citation Reports, the Impact Factor for a given year counts the number of citations received in that year by items published in the journal during the two preceding years, divided by the number of citable items published in those same two years. A value of 5.5 for 2022 therefore means that, on average, each citable article published in the journal during 2020 and 2021 was cited 5.5 times in 2022. Because the journal entered SciSearch in 2021, this figure reflects a relatively early citation window, which makes the performance even more striking. New entrants to the citation index typically take several years to accumulate visibility, so a first-quartile placement so soon after admission suggests an unusually rapid adoption by the research community.

The quartile classification adds another layer of meaning. Clarivate assigns journals to categories, and within each category journals are ranked by their Impact Factor and divided into quartiles, with Q1 representing the top 25 percent of titles. The Pharmacology and Pharmacy category is one of the largest and most competitive in the entire Web of Science taxonomy, encompassing 278 journals that range from mega-journals of translational medicine to highly specialized publications in toxicology, drug metabolism, and clinical pharmacy. Ranking 48th in that field places the Journal of Pharmaceutical Investigation firmly within the upper tier of pharmacological publishing, alongside far more established titles with decades of citation history. For authors weighing where to submit manuscripts, quartile placement often carries practical consequences, because funding agencies, promotion committees, and doctoral programs in many countries explicitly require publication in Q1 journals.

The journal’s subject scope helps explain its rising citation profile. Pharmaceutical investigation as a discipline sits at the crossroads of pharmaceutics, biopharmaceutics, drug delivery, pharmacokinetics, and formulation science, and it increasingly absorbs techniques from nanotechnology, materials science, and computational modeling. Research published under this umbrella includes studies of controlled-release systems, lipid-based carriers, polymeric nanoparticles, dissolution testing, bioavailability enhancement, and the physicochemical characterization of novel dosage forms. In recent years the field has been swept up in broader currents reshaping the pharmaceutical sciences, including the explosion of interest in mRNA delivery platforms, the refinement of long-acting injectable formulations, and the application of machine learning to formulation optimization. Journals positioned at the center of these currents tend to attract high citations, because their articles serve as methodological references for large and fast-moving research communities.

The journal in question is published by Springer, one of the major international scientific publishers, and the pharmaceutical sciences have long been a strategic area for the company’s portfolio. The relationship between publisher and index provider is central to the economics of modern scholarly communication. Publishers invest in editorial infrastructure, peer review management, digital preservation, and dissemination platforms, while citation index providers aggregate the resulting literature into evaluative frameworks that institutions use to allocate resources. The feedback loop can be powerful. Indexing increases discoverability through Web of Science searches, discoverability drives downloads and citations, and citations raise the Impact Factor, which in turn attracts stronger submissions from researchers seeking maximum visibility for their work. The journal’s 2022 numbers suggest that this flywheel has begun to turn decisively.

It is worth pausing on how rapidly scholarly metrics themselves have evolved, because the Impact Factor, despite its ubiquity, is a blunt instrument. Critics have long noted that the two-year citation window disadvantages slow-moving fields, that citation distributions within journals are heavily skewed so that a small fraction of papers accounts for most citations, and that aggregate scores can be gamed through editorial strategies such as publishing review articles, which attract citations at a higher rate than primary research. The San Francisco Declaration on Research Assessment, signed by thousands of journals and institutions, urges evaluators to look past journal-level metrics to the actual content and quality of individual papers. Yet the practical reality in much of the world, particularly in Asia, Europe, and Latin America, is that Impact Factors and quartiles remain embedded in grant applications, hiring decisions, and national research assessment exercises. Against that backdrop, a journal’s climb into Q1 translates directly into the career incentives of working scientists.

The pharmaceutical sciences occupy a distinctive position in this evaluative landscape because the field straddles academia and industry. Research on drug delivery and formulation frequently progresses from laboratory bench to clinical application, and the intellectual property and commercial stakes involved mean that citation patterns differ from those in purely academic disciplines. Industry scientists read and cite the pharmaceutical technology literature when designing development programs, and regulatory science considerations, such as bioequivalence standards and dissolution specifications, generate steady citation demand for foundational methodology papers. A Q1 journal in this space therefore functions not only as an academic outlet but as a shared reference point connecting university labs, contract research organizations, generic drug manufacturers, and innovator pharmaceutical companies across dozens of countries.

The timeline of the journal’s ascent is also instructive for understanding how new journals break through in a crowded market. Acceptance into SciSearch in 2021 followed the standard probationary logic of the Web of Science: emerging journals receive partial coverage initially, typically tracking newly published content, and their citation records build as indexed material accumulates. Within a single full cycle the journal achieved an Impact Factor of 5.5 and a category rank of 48 of 278, performance that many long-established titles would consider strong. This acceleration is characteristic of the current era, in which digital distribution, social media amplification, and global submission pipelines allow a well-edited journal to reach its audience far faster than was possible in the print-dominated decades when citation reputations took a generation to form.

For observers of scientific publishing, the broader lesson is that the map of influential journals is not fixed. The Pharmacology and Pharmacy category continues to expand, the tools for evaluating research continue to evolve, and the competition for high-quality manuscripts intensifies as publishers launch new open-access titles and established journals adjust their strategies. The Journal of Pharmaceutical Investigation’s 2022 standing, with an Impact Factor of 5.5 and a first-quartile ranking among 278 pharmacology journals, demonstrates how indexing prestige, editorial focus, and community engagement combine to reshape that map. Whether the journal can sustain and improve its position in future Journal Citation Reports will depend on the same factors that drive all scholarly success: the quality and novelty of the science it publishes, the rigor of its peer review, and its ability to serve as an indispensable resource for the researchers advancing drug development worldwide.

Subject of Research: Indexing and citation performance of the Journal of Pharmaceutical Investigation in the Web of Science Pharmacology and Pharmacy category

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Impact Factor, Science Citation Index Expanded, Web of Science, pharmacology, pharmacy, quartile ranking, citation metrics, drug delivery, pharmaceutical sciences, Springer, Q1 journal